StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.69+0.14 (+3.08%)

Close on Nov 18, 2026Market cap $2.33BP/E –Yield –

Regencell Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was -$11.72M. The highest annual figure on record is -$390.99K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$11.72M–
FY2025Jun 30, 2025-$3.77M–
FY2024Jun 30, 2024-$4.74M–
FY2023Jun 30, 2023-$6.27M–
FY2022Jun 30, 2022-$7.62M–
FY2021Jun 30, 2021-$1.38M–
FY2020Jun 30, 2020-$812.37K–
FY2019Jun 30, 2019-$390.99K–

More Regencell Bioscience figures

See a number that looks wrong?